Safety, immunogenicity and preliminary efficacy of multiple-site vaccination with an Epidermal Growth Factor (EGF) based cancer vaccine in advanced non small cell lung cancer (NSCLC) patients

Journal of Immune Based Therapies and Vaccines

Volumn 9, Issue , 2011, Pages

  Rodriguez, Pedro C ^a   Neninger, Elia ^b   García, Beatriz ^a   Popa, Xitlally ^a   Viada, Carmen ^a   Luaces, Patricia ^a   González, Gisela ^a   Lage, Agustin ^a   Montero, Enrique ^a,b   Crombet, Tania ^a  

^a CENTER OF MOLECULAR IMMUNOLOGY   (Cuba)

^b HOSPITAL CLINICOQUIRÚRGICO HERMANOS AMEIJEIRAS   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARRIER PROTEIN; CIMAVAX EGF; EPIDERMAL GROWTH FACTOR; PROTEIN P64K; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; ADVERSE OUTCOME; ANTIBODY RESPONSE; ARTICLE; ASTHENIA; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CHILL; DRUG EFFICACY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG SAFETY; FEMALE; HUMAN; IMMUNOGENICITY; INJECTION SITE REACTION; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NEISSERIA MENINGITIDIS; TREMOR;

EID: 80054814059     PISSN: None     EISSN: 14768518     Source Type: Journal    
DOI: 10.1186/1476-8518-9-7     Document Type: Article

References (22)

1. Gridelli C, Maione P, Rossi A, Palazzolo G, Colantuoni G, Rossi E. Management of unfit older patients with advanced NSCLC. Cancer Treatment Reviews 2009, 35:517-521. 10.1016/j.ctrv.2009.04.011, 19457617.
2. Gérard C, Debruyne C. Immunotherapy in the landscape of new targeted treatments for non-small cell lung cancer. Mol Oncol 2009, 3(5-6):409-24. 10.1016/j.molonc.2009.09.001, 19846354.
3. Merlo V, Longo M, Novello S, Scagliotti GV. EGFR pathway in advanced non-small cell lung cancer. Front Biosci 2011, 3:501-17.
4. Trigo Pérez JM, Garrido López P, Felip Font E, Isla Casado D, . SEOM (Spanish Society for Medical Oncology) SEOM clinical guidelines for the treatment of non-small-cell lung cancer: an updated edition. Clin Transl Oncol 2010, 11:735-41. SEOM (Spanish Society for Medical Oncology).
5. Gridelli C, De Marinis F, Di Maio M, Cortinovis D, Cappuzzo F, Mok T. Gefitinib as first-line treatment for patients with advanced non-small-cell lung cancer with activating epidermal growth factor receptor mutation: Review of the evidence. Lung Cancer 2011, 71(3):249-57. 10.1016/j.lungcan.2010.12.008, 21216486.
6. Pirker R, Pereira JR, Szczesna A, von Pawel J, Krzakowski M, Ramlau R, Vynnychenko I, Park K, Yu CT, Ganul V, Roh JK, Bajetta E, O'Byrne K, de Marinis F, Eberhardt W, Goddemeier T, Emig M, Gatzemeier U, . FLEX Study Team Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomized phase III trial. Lancet 2009, 373(9674):1525-31. 10.1016/S0140-6736(09)60569-9, 19410716, FLEX Study Team.
7. Rodríguez PC, Rodríguez G, González G, Lage A. Clinical development and perspectives of CIMAvax EGF, Cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev 2010, 12(1):17-23.
8. González G, Crombet T, Catalá M, Mirabal V, Hernández JC, González Y, Marinello P, Guillén G, Lage A. A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: report of a pilot clinical trial. Ann Oncol 1998, 9(4):431-5. 10.1023/A:1008261031034, 9636835.
9. Gonzalez G, Crombet T, Torres F, Catala M, Alfonso L, Osorio M, Neninger E, Garcia B, Mulet A, Perez R, Lage R. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann Oncol 2003, 14(3):461-6. 10.1093/annonc/mdg102, 12598354.
10. Ramos T, Vinageras E, Catala M, Garcia B, Leonard I, Martinez L, Gonzalez G, Perez R, Lage A. Treatment of NSCLC Patients with an EGF-Based Cancer Vaccine: report of a Phase I trial. Cancer Biol Ther 2006, 5(2):130-40.
11. González G, Crombet T, Neninger E, Viada C, Lage A. Therapeutic vaccination with epidermal growth factor (EGF) in advanced lung cancer: analysis of pooled data from three clinical trials. Hum Vaccin 2007, 3(1):8-13. 10.4161/hv.3.1.3537, 17204867.
12. Neninger Vinageras E, de la Torre A, Osorio Rodríguez M, Catalá Ferrer M, Bravo I, Mendoza del Pino M, Abreu Abreu D, Acosta Brooks S, Rives R, del Castillo Carrillo C, González Dueñas M, Viada C, García Verdecia B, Crombet Ramos T, González Marinello G, Lage Dávila A. Phase II randomized controlled trial of an epidermal growth factor vaccine in advanced NSCLC. J Clin Oncol 2008, 26(9):1452-8. 10.1200/JCO.2007.11.5980, 18349395.
13. Neninger E, Verdecia BG, Crombet T, Viada C, Pereda S, Leonard I, Mazorra Z, Fleites G, González M, Wilkinson B, González G, Lage A. Combining an EGF based cancer vaccine with chemotherapy in advanced non small cell lung cancer. J Immunotherapy 2009, 32(1):92-9.
14. García B, Neninger E, de la Torre A, Leonard I, Martínez R, Viada C, González G, Mazorra Z, Lage A, Crombet T. Effective inhibition of the epidermal growth factor/epidermal growth factor receptor binding by anti-epidermal growth factor antibodies is related to better survival in advanced non-small-cell lung cancer patients treated with the epidermal growth factor cancer vaccine. Clin Cancer Res 2008, 14(3):840-6. 10.1158/1078-0432.CCR-07-1050, 18245547.
15. Gonzalez G, Montero E, Leon K, Cohen IR, Lage A. Autoimmunization to epidermal growth factor, a component of the immunological homunculus. Autoimmun Rev 2002, 1(1-2):89-95. 10.1016/S1568-9972(01)00015-5, 12849064.
16. Rodriguez PC, Gonzalez I, Gonzalez A, Avellanet J, Lopez A, Perez R, Lage A, Montero E, . Source Priming and boosting determinants on the antibody response to an Epidermal Growth Factor-based cancer vaccine. Vaccine 2008, 26(36):4647-54. 10.1016/j.vaccine.2008.07.003, 18640164, Source.
17. Jaffee EM, Thomas MC, Huang AY, Hauda KM, Levitsky HI, Pardoll DM. Enhanced immune priming with spatial distribution of paracrine cytokine vaccines. J Immunother Emphasis Tumor Immunol 1996, 19(3):176-83.
18. Couch M, Saunders JK, O'Malley BW, Pardoll D, Jaffee E. Spatial distribution of tumor vaccine improves efficacy. Laryngoscope 2003, 113(8):1401-5. 10.1097/00005537-200308000-00026, 12897566.
19. Osorio M, Gracia E, Rodríguez E, Saurez G, Arango Mdel C, Noris E, Torriella A, Joan A, Gómez E, Anasagasti L, González JL, Melgares Mde L, Torres I, González J, Alonso D, Rengifo E, Carr A, Pérez R, Fernández LE. Heterophilic NeuGcGM3 ganglioside cancer vaccine in advanced melanoma patients: results of a Phase Ib/IIa study. Cancer Biol Ther 2008, 7(4):488-95. 10.4161/cbt.7.4.5476, 18285705.
20. Santin AD, Bellone S, Palmieri M, Zanolini A, Ravaggi A, Siegel ER, Roman JJ, Pecorelli S, Cannon MJ. Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial. J Virol 2008, 82(4):1968-79. 10.1128/JVI.02343-07, 2258728, 18057249.
21. Wolchok JD, Yuan J, Houghton AN, Gallardo HF, Rasalan TS, Wang J, Zhang Y, Ranganathan R, Chapman PB, Krown SE, Livingston PO, Heywood M, Riviere I, Panageas KS, Terzulli SL, Perales MA. Safety and immunogenicity of tyrosinase DNA vaccines in patients with melanoma. Mol Ther 2007, 15(11):2044-50. 10.1038/sj.mt.6300290, 17726460.
22. Zinkernagel RM, Hengartner H. Regulation of the immune response by antigen. Science 2001, 293(5528):251-3. 10.1126/science.1063005, 11452115.